Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 14, 2012

View Archived Issues

New therapeutic target identified for schizophrenia

Nanoparticles targeting microRNA inhibit lymphoma

Novo Nordisk announces highlights of second quarter 2012

MultiCell Technologies updates on candidate dsRNA anticancer therapies

Protalix BioTherapeutics to begin clinical testing of candidate Fabry's disease drug

Bionor Pharma to conduct HIV vaccine combination study

AspenBio Pharma submits pre-IDE package for appendicitis test

Biofrontera and Pelpharma Handels sign distribution agreement

Scientists in China isolate new saponins from bunge fruit

Canadian university patents novel melanocortin MC4 receptor modulators

Compounds for ADHD treatment synthesized in France

New glutamate receptor antagonists presented by Taisho Pharmaceutical

Novel calcium channel antagonists developed at U.S. university

Nagasaki University reports new candidate anticancer products

Meritage Pharma launches trial in eosinophilic esophagitis

Recruitment complete in first stage of TACTT1 study

FDA extends PDUFA action date for Gattex NDA

Novel HCV entry inhibitor selected for further evaluation

New E.U. approval for Votrient

Second-generation Shigella vaccines designed in U.S.

PDUFA date for Santarus NDA extended

Tarceva approved in Canada for specific NSCLC subtype

FDA accepts for filing Teva's NDA for new oral contraceptive

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...